Related Experiment Video

Updated: May 13, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Association of P2X7R gene polymorphisms with systemic lupus erythematosus in a Chinese population

Gui-Mei Chen1, Chen-Chen Feng, Qian-Ling Ye

  • 1Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, Anhui 230032, People's Republic of China.

Mutagenesis
|February 26, 2013
PubMed

Insights

Genetic variations in the P2X7 receptor gene (P2X7R) are linked to systemic lupus erythematosus (SLE) risk in the Chinese population. Specific single-nucleotide polymorphisms (SNPs) like rs1718119 show a protective effect against SLE development.

Area of Science:

  • Immunogenetics
  • Rheumatology
  • Molecular Biology

Background:

  • The P2X7 receptor (P2X7R) is an ATP-gated ion channel expressed on immune cells, crucial for inflammatory responses.
  • Dysregulation of P2X7R signaling is implicated in autoimmune diseases like systemic lupus erythematosus (SLE).
  • The P2X7R gene exhibits significant polymorphism, with single-nucleotide polymorphisms (SNPs) potentially influencing disease susceptibility.

Purpose of the Study:

  • To investigate the association between P2X7R gene SNPs (rs1718119, rs2230911, rs3751143) and susceptibility to SLE in a Chinese cohort.
  • To explore the potential role of these SNPs in SLE with nephritis (LN).

Main Methods:

  • A case-control study involving 535 Chinese SLE patients and 532 healthy controls.
  • Genotyping of P2X7R SNPs rs1718119, rs2230911, and rs3751143 using standard methods.
  • Statistical analysis including odds ratios (OR) and confidence intervals (CI) to assess genetic associations and haplotype analysis.

Main Results:

  • The rs1718119 SNP was significantly associated with reduced SLE risk (A allele carriers and specific genotypes showed lower risk).
  • No significant association was found for rs2230911 and rs3751143 with overall SLE susceptibility.
  • For SLE with nephritis, the rs2230911 G allele and related genotypes were associated with a lower risk of LN.
  • The ACA haplotype of P2X7R was identified as a protective factor against SLE.

Conclusions:

  • The P2X7R gene, particularly the rs1718119 polymorphism, may play a role in SLE susceptibility within the Chinese population.
  • Specific P2X7R variants might influence the risk of developing lupus nephritis.
  • Further research is warranted to elucidate the functional impact of these genetic variations on P2X7R activity and SLE pathogenesis.

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pleiotropy01:33

Pleiotropy

Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...